Phase III study of cyclophosphamide, doxorubicin, and fluorouracil (CAF) plus leucovorin versus CAF for metastatic breast cancer: Cancer and Leukemia Group B 9140.

@article{Minasian2003PhaseIS,
  title={Phase III study of cyclophosphamide, doxorubicin, and fluorouracil (CAF) plus leucovorin versus CAF for metastatic breast cancer: Cancer and Leukemia Group B 9140.},
  author={Lori M. Minasian and Constance T. Cirrincione and Joseph Aisner and Donald Berry and Steven L. Allen and Judith Abrams and Ernest Chuang and Michael Robert Cooper and Michael C. Perry and David B. Duggan and Ted P. Szatrowski and M. D. I.Craig Henderson and L. Norton},
  journal={Journal of clinical oncology : official journal of the American Society of Clinical Oncology},
  year={2003},
  volume={21 9},
  pages={
          1819-24
        }
}
PURPOSE To determine whether biochemical modulation with LV (leucovorin) enhances the efficacy of CAF (cyclophosphamide, doxorubicin, and fluorouracil) against metastatic breast cancer. PATIENTS AND METHODS Women with histologically confirmed stage IV breast cancer, Cancer and Leukemia Group B (CALGB) performance status 0 to 2, and no prior chemotherapy for metastatic disease were randomly assigned to receive CAF (cyclophosphamide 500 mg/m2 day 1, doxorubicin 40 mg/m2 day 1, and fluorouracil… CONTINUE READING
BETA

Similar Papers

Citations

Publications citing this paper.
SHOWING 1-10 OF 15 CITATIONS

What is the role of chemotherapy in estrogen receptor-positive, advanced breast cancer?

  • Annals of oncology : official journal of the European Society for Medical Oncology
  • 2009
VIEW 1 EXCERPT
CITES BACKGROUND